JXJing Xue

Jing Xue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing Xue has a total of 399 co-authors. Here are the top co-authors by number of shared publications:

  • Jiahan Lu

    NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College

    20 shared publications
  • Ting Chen

    NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China

    18 shared publications
  • Jingjing Zhang

    NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China

    17 shared publications
  • Zhe Cong

    NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China

    17 shared publications
  • Qiang Wei

    Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

    14 shared publications
  • Na Li

    NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College

    13 shared publications

Latest Publications

  • Open Access

    Analysis of pathological changes and virus-susceptible cells in the testes following MPXV infection in a rhesus macaque model

    by Jia-Tong Chang, Kun-Qi Lin, Li-Bo Liu, Wei Yang, Dong-Ying Fan, Jing Xue, Pei-Gang Wang, Jing An

  • Open Access

    A four-amino-acid deletion in gp41 enhances HIV-1 CRF01_AE Cluster 4 pathogenicity and fusion inhibitor resistance

    by Dong Zhang, Jingwan Han, Chang Liu, Jiahan Lu, Na Li, Jiasen Yang, Fei Wang, Yinuo Li, Yujie Sun, Dandan Lin, et al.

    HIV-1 CRF01_AE Cluster 4 strains are spreading rapidly in China and Southeast Asia, yet the molecular characteristics and pathogenic mechanisms remain to be fully characterized. Here, we identified a characteristic RSSL tetrapeptide deletion in the gp41 region of CRF01_AE Cluster 4 strains. Compared with a Cluster 5 control strain (GX-C5), the RSSL-deficient mutant GX-C4 exhibited a higher replication peak in MT-4 cells, outcompeted the GX-C5 control in co-culture, and showed significantly enhanced infectivity in TZM-bl and MT-2 cells, accompanied by increased fusion activity but no difference in viral attachment. GX-C4 also showed reduced susceptibility to the fusion inhibitor Enfuvirtide (T20), with a 1.67-fold increase in IC 50 , and displayed even greater resistance to LP-98 (a novel and potent fusion inhibitor), with an approximately 12-fold increase in IC 50 . Further experiments revealed that RSSL mutation does not upregulate intracellular Env expression but significantly enhances Env incorporation into virions. Transcriptomic analysis identified 61 strain-specific differentially expressed genes between GX-C4- and GX-C5-infected groups, which were enriched in pathways related to muscle cytoskeleton regulation and motor protein function. The myosin gene MYH4 was significantly downregulated in GX-C4-infected cells, and the expression of the key immune molecule TICAM2 was also suppressed. The differential expression of these genes in host cells may further contribute to the differences in viral pathogenicity. Collectively, RSSL deletion significantly enhances viral pathogenic characteristics and reduces drug susceptibility, likely by promoting cytoskeletal rearrangement, and enhancing membrane fusion. These findings provide important theoretical insights into the differential pathogenicity of HIV-1 CRF01_AE Clusters 4 and 5. IMPORTANCE: This study identifies the RSSL tetrapeptide deletion in the gp41 region as a key molecular signature of CRF01_AE Cluster 4 strains and demonstrates its central role in enhancing viral replication capacity and resistance to fusion inhibitors through modulation of viral fusion efficiency. Notably, the RSSL-deleted strain exhibited up to 12-fold increased resistance to the clinical fusion inhibitor LP-98, suggesting that this deletion may impact therapeutic efficacy. Transcriptomic analysis further reveals enrichment in cytoskeletal pathways, the significant downregulation of MYH4 offering potential new targets for antiviral intervention. These findings provide a critical scientific basis for understanding the molecular evolution of CRF01_AE clusters, informing epidemic surveillance, and optimizing treatment strategies.

  • Open Access

    An experimentally validated structure-based computational framework for humanisation of anti-orthopoxvirus antibodies

    by Xuehua Yang, Xuemeng Dong, Jiahan Lu, Xiaojing Chi, Xiuying Liu, Huarui Duan, Peixiang Gao, Jing Xue, Wei Yang

  • Open Access

    Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A

    by Lu Jin, Yuqi Zhu, Fan Yang, Ting Chen, Xinyi Yang, Yuan Tang, Yipeng Cheng, Dengji Zhang, Jingna Xun, Jun Liu, et al.

    Background/Objectives: AIDS is a serious threat to human health and remains incurable; however, EK-16A, an ingenol derivative, shows promise as a functional cure. In this study, we aimed to extract EK-16A from Euphorbia kansui, used in traditional Chinese medicine, to develop an oral self-nanoemulsifying drug delivery system (SNEDDS) for EK-16A and evaluate it in vivo. Methods: EK-16A was purified by SFC combined with conventional extraction. The optimal SNEDDS formulation was selected by emulsification and stability testing. Pharmacokinetics, metabolomics, and proteomics were used for in vivo evaluation. Results: 1. The extraction yield of EK-16A was four times higher than that of the conventional process; the extraction scale was increased by 25 times, and the purity of EK-16A reached 98.0%. 2. EK-16A is a BCS Class IV compound with low solubility and permeability. The compound’s content degraded to 49.8% after 3 months at 25 °C/60% RH. The EK-16A SNEDDS formulation A#1 showed no degradation after 3 months at 40 °C/75% RH. The absolute bioavailability after oral administration of formulation A#1 in rats was 0.445%. 3. The proteomics results showed that EK-16A significantly downregulated the PI3K-AKT signaling pathway in SHIV-infected rhesus macaques. Specifically, all 11 identified differential proteins were significantly downregulated. Conclusions: 1. The extraction process for EK-16A features high yield, purity and large scale. 2. The SNEDDS formulation enhances the stability of EK-16A and successfully delivers this low-solubility and permeability compound into the systemic circulation. 3. Proteomics analysis revealed that EK-16A significantly downregulates the PI3K-AKT signaling pathway in SHIV-infected rhesus macaques. However, further experiments, such as measuring plasma viremia and cell-associated SHIV RNA, are needed to confirm this mechanism.

  • Open Access

    Dose‐dependent pathogenicity and inflammatory imbalance in severely immunodeficient mice infected with mpox virus

    by Na Li, Ziqing Jia, Zhe Cong, Jianrong Ma, Jiahan Lu, Yongzhi Hou, Fei Wang, Jiasen Yang, Ting Chen, Jingjing Zhang, et al.

    The global spread of mpox continues to pose a threat to public health, with immunocompromised patients being at greater risk for severe disease. This study aimed to establish a lethal severe infection model using NPG (NOD.Cg‐ Prkdc scid Il2rg tm1 /Vst) mice, a strain with profound immunodeficiency, to simulate severe mpox in immunocompromised patients and investigate disease progression, viral replication kinetics, tissue tropism, and immune responses. In our study, mice were inoculated with three doses of mpox virus (high: 2 × 10 7 , medium: 2 × 10 6 , low: 2 × 10 5 TCID 50 [50% tissue culture infective dose]) or phosphate‐buffered saline as a negative control. Body weight, clinical signs, and survival were monitored. Viral loads in plasma and tissues, histopathological changes, and inflammatory responses were evaluated to systematically characterize the pathogenicity of mpox virus in severely immunodeficient mice. The results showed that NPG mice were highly susceptible to mpox virus, showing a clear dose‐dependent response. The high‐dose group exhibited 100% lethality, and the medium‐dose group had a 50% survival rate, whereas the low‐dose and control groups survived throughout the study. Plasma and tissue viral loads, as well as histopathological severity, followed a dose‐dependent pattern. Viremia remained persistently high, and animals that died at different time points exhibited uniformly high viral loads across multiple tissues. By day 10 postinfection, markedly elevated levels of pro‐inflammatory cytokines were detected in plasma, whereas anti‐inflammatory cytokines remained largely uninduced. We found that the infection of severely immunodeficient mice with mpox virus results in dose‐dependent lethality, persistent high viral loads, and a pronounced pro−/anti‐inflammatory imbalance. These findings provide important insights into the pathogenesis of mpox in immunocompromised populations and develop a practical animal model for evaluating therapeutic interventions.

  • Open Access

    Comparative virology and pathology of Monkeypox virus in Syrian hamsters, C57BL /6, and BALB /c mice: A framework for preclinical model selection

    by Xiaohui Wei, Jing Wu, Hekai Yang, Na Li, Binbin Zhao, Wanjun Peng, Na Rong, Wei Zhang, Jing Xue, Jiangning Liu

    Monkeypox virus (MPXV), a zoonotic orthopoxvirus, has emerged as a major public health concern following its global spread in 2022. Robust small animal models are urgently needed to investigate MPXV pathogenesis and evaluate medical countermeasures. Here, we systematically compared MPXV infection in Syrian hamsters, C57BL/6 mice, and BALB/c mice following intraperitoneal inoculation. Syrian hamsters displayed the highest susceptibility, with systemic viral dissemination peaking at 2 days post‐infection (dpi) and clearance by 12 dpi. Viral burdens were particularly elevated in the spleen and kidneys, correlating with severe histopathological changes. In contrast, C57BL/6 and BALB/c mice exhibited more restricted viral replication, with the kidneys, liver, and spleen serving as major target organs. Across all models, no cutaneous lesions were observed, underscoring the influence of infection route on disease phenotype. Comparative analysis revealed species‐specific tissue tropism and clearance kinetics, confirming the Syrian hamster as a permissive model for systemic MPXV disease, while C57BL/6 and BALB/c mice offer complementary value for mechanistic immunology studies. These findings establish a framework for rational selection of small animal models to study MPXV pathogenesis and to evaluate antiviral and vaccine strategies.

  • Open Access

    Development of a replication-defective mpox virus platform for fundamental and therapeutic research

    by Jiannan Chen, Liyuan Hu, Riccardo Vernuccio, Ning Shi, Jiaxin Tian, Yuyi Zhang, Sicheng Tian, Xinyu Cao, Zhuo Ha, Jiahan Lu, et al.

    The recent global outbreaks of mpox highlight the urgent need for both fundamental research and antiviral development. However, studying the mpox virus (MPXV), with its large and complex genome, remains challenging due to the requirement for high-containment facilities. Here, we describe a strategy for de novo assembly of MPXV clade IIb genomes in bacterial artificial chromosomes using transformation-associated recombination cloning. Leveraging CRISPR-Cas9 and Lambda Red recombination, we engineer replication-defective MPXV particles with dual deletions of OPG96 (M2R) and OPG158 (A32.5 L)—genes essential for virion assembly, that are capable of recapitulating key stages of the viral life cycle. We apply this system to screen a compound library and identify G243-1720, a potent anti-poxvirus inhibitor with broad activity in vitro and in vivo. G243-1720 blocks the formation of extracellular enveloped virions and cell-cell spread. Resistance mutation selection, crystallographic analysis, analytical ultracentrifugation, and mass photometry reveal that, despite its distinct chemical structure, G243-1720 shares a mode of action with tecovirimat, both functioning by affecting dimerization of protein OPG57 (F13). Our findings underscore the potential of G243-1720 as a promising broad-spectrum anti-poxvirus lead compound and demonstrate the utility of replication-defective MPXV particles as a reliable platform for viral biology studies and antiviral development.


  • Hexakisphosphate (IP6) potentiates HIV-1 maturation inhibitor binding at the CA-SP1 junction: insights from molecular modeling and biophysical assays

    by Zixuan Zhao, Yinghong Ma, Ji Zhang, Yong Xie, Bing Li, Xiaoming Yang, Xiaohong Zhao, Zhonghao Sun, Haiyue Hu, Zhaocui Sun, et al.


  • Open Access

    Anti-M1R/B6R antibody characterization and bispecific design for enhanced orthopoxvirus protection

    by Runchu Zhao, Lili Wu, Yi Zhang, Jianrong Ma, Dezhi Liu, Yuxuan Zheng, Tianxiang Kong, Renyi Ma, Zhengrong Gao, Yan Chai, et al.

    The global outbreak of the mpox in humans, caused by the mpox virus (MPXV), underscores the urgent need for safe and effective therapeutics. In this study, we characterized the dominant MPXV immunogens, M1R and B6R, by sequencing monoclonal antibodies (MAbs) from the immunized mice and analyzing their epitopes and functions through in vitro and in vivo assessments of binding and antiviral activities. Several broadly effective anti-M1R and anti-B6R neutralizing MAbs were identified and they exhibited enhanced antiviral effects against MPXV or vaccinia virus (VACV) when used in antibody cocktail and bispecific antibody designs. Notably, the VH-CH1 switch region-inserting format of bispecific antibodies exhibited robust protective efficacy against VACV in a mouse model. Collectively, our study characterized the epitope and functional maps of anti-M1R and anti-B6R MAbs and developed promising broad-spectrum antibody candidates for the treatment of MPXV and other orthopoxvirus infections.


  • Open Access

    An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques

    by Jing Xue, Yuanmei Zhu, Chenbo Yang, Xiaosheng Liu, Rui Hou, Wei Wang, Huihui Chong, Zhe Cong, Jingjing Zhang, Ling Tong, et al.